Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors

NCT00024661 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: LErafAON

Sponsor

INSYS Therapeutics Inc

Collaborators

[object Object]